Cyfuse Biomedical K.K.
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Cyfuse Biomedical K.K. made a loss over the last year. Cyfuse Biomedical K.K. owes ¥0.33 for every ¥1 it owns. Cyfuse Biomedical K.K. made a loss in each of the last two years.
Compared with Healthcare companies in Japan · latest annual results Dec 2025.
P/E ratio
LossCyfuse Biomedical K.K. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
2.17The share price is 2.17 times Cyfuse Biomedical K.K.'s book value per share, higher than 68% of Healthcare companies in Japan.
Market cap
¥5.7 BThe total market value of all of Cyfuse Biomedical K.K.'s shares at today's price (share price × number of shares), smaller than 77% of Healthcare companies in Japan. PosiCap size class: Micro Cap.
Net worth (book value)
¥2.6 BWhat Cyfuse Biomedical K.K. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
¥259.83Net worth divided by the number of shares. The share price of ¥564.00 is 2.2 times this, which is the P/B above.
Return on equity (ROE)
-32.1%Cyfuse Biomedical K.K. lost 32.1% of its shareholders' money over the last year, lower than 84% of Healthcare companies in Japan.
Owes vs Owns
0.33×Cyfuse Biomedical K.K. owes ¥0.33 for every ¥1 it owns (low), lower than 54% of Healthcare companies in Japan.
Dividend yield
NoneCyfuse Biomedical K.K. does not currently pay a dividend.
Revenue growth
+324%Revenue rose 324% in the year to Dec 2025, and shrank 15% a year on average over 3 years.
Profit growth
LossCyfuse Biomedical K.K. made a loss in each of the last two years.
Profit margin
-330.7%Cyfuse Biomedical K.K. lost ¥331 for every ¥100 of revenue.
Interest cover
Not coveredCyfuse Biomedical K.K.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashCyfuse Biomedical K.K. held ¥2.4 B more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Cyfuse Biomedical K.K.: ¥5.7 B ÷ ¥2.6 B (30 Jun 2026) = 2.2.
What is Cyfuse Biomedical K.K.'s return on equity?
Cyfuse Biomedical K.K. lost 32.1% of its shareholders' money over the last year, lower than 84% of Healthcare companies in Japan.
How much does Cyfuse Biomedical K.K. owe compared with what it owns?
Cyfuse Biomedical K.K. owes ¥0.33 for every ¥1 it owns (low), lower than 54% of Healthcare companies in Japan.
Does Cyfuse Biomedical K.K. pay a dividend?
No. Cyfuse Biomedical K.K. does not currently pay a dividend.
Is Cyfuse Biomedical K.K.'s revenue growing?
Revenue rose 324% in the year to Dec 2025, and shrank 15% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.